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Abstract
Urine represents a valuable biofluid for noninvasive measurement of Human Growth Hormone (HGH) secretion. 
Unfortunately, currently available commercial HGH immunoassays do not achieve the sensitivity needed for urinary 
HGH measurement in the low picogram per milliliter range, the expected normal concentration range of HGH in urine.
A nanotechnology based sample preprocessing step was used to extract and concentrate HGH in urine so that 
urinary HGH could be measured with a clinical grade standard immunoassay designed for serum (Immulite 1000, 
Siemens). We applied the nanoparticle enhanced immunoassay to evaluate the baseline value of urinary HGH in a 
population of healthy young adults (age 18-30, N=33, median 21, M: F=39%:61%, with no reported medical therapies).
Nanoparticle sample preprocessing effectively improved the lower limit of detection of the Immulite HGH assay 
by more than 50 fold, shifting the linear range of the assay to encompass the expected value of urinary HGH. The full 
process between run and within run CV% was 7.9 and 9.0%, respectively. On 33 healthy volunteers, the 95% reference 
values for hGH in spot urine normalized to specific gravity were 0.64 - 16.85 pg/mL (0.05 -5.82 ng/g creatinine).
Nanoparticle preprocessing constitutes a reliable means of measuring urinary HGH with a clinical grade 
immunoassay, now establishing a normal baseline value for HGH in urine. Nanoparticles can be used to study the 
kinetics of HGH excretion in urine, and the factors that influence urinary HGH secretion and HGH isoform proportions. 
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Introduction
The importance of measuring Human Growth Hormone (HGH) 
levels in the clinical chemistry laboratory is growing rapidly for several 
reasons. Firstly, therapeutic administration of hGH has expanded 
beyond the treatment of short stature to now encompass traumatic 
brain injury [1], Turner syndrome [2] and aging [3]. Secondly, the 
abuse of hGH supplementation for enhancement of sport performance 
is believed to be widely prevalent [4]. While hGH testing is usually done 
in serum, there is a growing need for the measurement of hGH in urine 
[5,6]. Urine represents a valuable biofluid for noninvasive measurement 
of HGH secretion [7]. Unfortunately, currently available commercial 
HGH immunoassays, not based on radioactive labels, do not achieve 
the sensitivity needed for urinary HGH measurement. The Lower 
Limit of Detection (LLD) of the Immulite HGH serum immunoassay, 
Immulite 1000 (Siemens) is 50 pg/mL, a value similar to the LLD for 
the current commercial (non-radiometric) immunoassays for HGH 
or its isoforms in blood [8]. This LLD is 50 fold above the postulated 
concentration of urinary hGH in healthy individuals, estimated to be 
in the range of 1 pg/mL, as reported using ultrafiltration concentration 
and radioimmunoassay measurements conducted in the 1990s [7,9]. 
Thus, despite the fact that clinical researchers and basic scientists in 
the field of hGH research urgently need a simple and reliable assay for 
hGH in urine [6], commercial immunoassays designed for serum cannot 
be used for urine hGH testing. To address this need, in the present study 
we have applied hydrogel harvesting nanoparticles as a preprocessing step 
for HGH measurement in urine.  Nanoparticles are added to the urine 
samples to concentrate the analyte into a small volume, which can then be 
eluted and measured by a clinical grade standard immunoassay designed 
for serum (Figure 1). The nanoparticles can rapidly harvest, protect from 
degradation, and concentrate, low abundance analytes from biologic fluids 
while actively excluding high abundance proteins such as albumin [10-13]. 
Applied as a simple one-step biospecimen pre-processing addition, 
the nanoparticles can improve the lower limit of analyte detection while 
preserving the linearity and precision of the analytical platform. In this 
study, we applied analyte harvesting hydrogel nanoparticles [10,11] 
to reduce the LLD of the Immulite clinical serum immunoassay for 
HGH. The Immulite Growth Hormone (HGH) (Recombinant 98/574) 
is a standard two site sandwich immunoassay which reports a lower of 
detection of 0.050 ng/mL. The nanoparticle preprocessing as described 
herein, reduces the LLD by more than 50 fold, shifting the linear range 
of the assay to encompass the expected value of urinary HGH. Here 
we report the use of nanoparticle preprocessing to establish an initial 
reference range value for urinary human growth hormone (hGH) in 
healthy young adults (age 18-30, N=33, median 21, M:F=39%:61%, 
with no reported medical therapies), using the Immulite hGH serum 
immunoassay, Immulite 1000 (Siemens).
Materials and Methods
Subjects
We collected urine and blood from 33 healthy young adults (age 
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18-30, median 21, M:F=39%:61%, with no reported medical therapies). 
Spot urine (> 30 mL) collections were done in a standardized time 
period in the morning (10 to 11 AM). The study was approved by the 
George Mason University Human Subjects Review Board (protocol 
GMU # 6081) and conformed to the code of ethics of the world medical 
association (Declaration of Helsinki), printed in the British Medical 
Journal (18 July 1964). All subjects gave written informed consent.
Nanoparticle synthesis 
Poly N-isopropylacrylamide (NIPAm) co- Acrylic Acid (AAc) 
nanoparticles were produced by precipitation polymerization and 
covalently linked to the chemical reactive dyes via zero link amidation 
reaction [10]. 
In order to prepare poly (NIPAm-co-AAc) particles, 4.750 grams of 
NIPAm (Aldrich) and 0.400 grams of N, N’ -methylenebisacrylamide 
(BIS, Aldrich) were dissolved in 500 ml of Milli-Q water. The solution 
was filtered under vacuum and transferred to a three neck round 
bottom flask under medium stirring. 500 µl (0.525 gr) of AAc (Sigma 
Aldrich) was added to the round-bottom flask and the solution was 
purged with nitrogen for 30 minutes. The temperature of the solution 
was increased to 70°C and held constant for 15 minutes. 0.276 grams 
of Potassium  persulfate (KPS, Sigma Aldrich) were dissolved in 5 mL 
of water and added to the round bottom flask. The reaction was help 
at 70°C for six hours and let cool overnight. Unreacted monomer was 
washed by centrifugation (19,000 rpm, 50 minute, 20°C) with MilliQ 
water. Particles were re-suspended in a final volume of 600 mL.
In order to covalently link organic reactive dyes to poly (NIPAm-
co-AAc) particles, a preliminary activation of the carboxylic group 
present in the nanoparticles was performed. Briefly, 20 mL of particle 
suspension prepared as described before were re-suspended in 0.2 M 
Monobasic Phosphate Sodium (NaH2PO4) pH 5. The particle suspension 
was transferred in a round flask and 1 mL of 1% SDS (w/v), 824 mg 
of N-(3 Dimethylaminopropyl) N’ ethyl carbodiimide hydrochloride 
(EDC; Fluka Analytical) and 612 of solid N-Hydroxysuccinimide (NHS; 
Sigma-Aldrich) were added. The reaction was held at room temperature 
and medium stirring rate for 15 minutes. Meanwhile, organic dye 
(Remazol Brilliant Blue R, Sigma = 0.151 g, Acid Blue 22, Sigma = 0.178 
g, Brilliant Blue R250, Fisher = 0.2 g, Cibacron Blue F3GA, Polysciences 
= 0.2 g, Rhoda mine 123, Sigma = 0.09 g) was dissolved in  50 mL of 
0.2 M Dibasic Phosphate Sodium (Na2HPO4) pH 9 and filtered through 
a 0.22 µm cellulose acetate membrane (Corning). Due to inferior 
solubility in aqueous buffers, the dyes Disperse Orange 3, Sigma = 
0.058 g, Pararosaniline Base, Sigma =0.073 g were dissolved in 25 ml of 
ethanol, 5 ml of 1% SDS and 25 ml of 0.2 M Na2HPO4 pH 9 and filtered 
through a 0.22 µm cellulose acetate membrane (Corning). After 15 
minutes of activation reaction, the particle suspension was centrifuged 
(16.1 rcf, 15 minutes, 25°C), the supernatant was discarded and the 
particle pellet was re-suspended in the dye solution. The reaction was 
held at room temperature at medium stirring rate overnight. In order 
to eliminate the un-reacted dye, particles were washed ten times with 
water by centrifugation (19,000 rpm, 50 minutes, 25°C). Supernatants 
were disposed and particles re-suspended in 20 mL of MilliQ water.
Nanoparticle characterization
Particles were characterized by atomic force microscopy (AFM) 
using an NSCRIPTOR™ DPN® System (NanoInk). Particles solution (1 
µg/ml) was deposited on freshly cleaved mica under humid atmosphere 
for 15 minutes and dried under nitrogen before measurement. Images 
were acquired under AC mode using a silicon tip with a typical 
resonance frequency of 300 kHz and a radius smaller than 10 nm. 
Incorporation of dye in the particles was assessed by weighing the dry 
particles before and after dye coupling.
Urinalysis, specific gravity and creatinine measurement
Dipstick urinalysis, specific gravity and creatinine measurement 
were performed on freshly collected urine before particle incubation. 
Urinalysis was performed with Siemens Multistix 10SG. Specific gravity 
was measured by means of a digital refractometer (Atago). Creatinine 
was measured by Creatinine Parameter Assay Kit (R&D systems) 
according to the manufacturer instructions.
Nanoparticle preprocessing of urine
Aliquots of 30 mL of urine were centrifuged (3,000 rpm, 10 minutes, 
20°C) in order to remove cell debris. Urine pH value was measured 
by and adjusted to 5 with 1 M HCl if necessary. Urine was incubated 
with 3 mL of poly (NIPAm/RBB) nanoparticles for 30 minutes. The 
nanoparticles were separated by centrifugation (20,000 rpm, 40 
minutes, 25°C). Protein cargo was eluted with 70% acetonitrile 10% 
ammonium hydroxide and dried under nitrogen flow (Organomation). 
Immulite 1000 growth hormone immunoassay
The concentration of HGH eluted from particles was measured using 
the Immulite 1000 Immulite Growth Hormone (HGH) (Recombinant 
98/574) (Siemens Medical Solution Diagnostic). Particle eluates were 
dried under nitrogen flow, the dried proteins were dissolved in 0.3 mL 
of Immulite GH sample diluent and hGH was measured according to 
manufacturer instructions for serum hGH. 
Statistical analysis
Reference values and confidence intervals were calculated with the 
bootstrap method [14] in R Statistical Software [15].
Results
Nanoparticle bait screening
A key element of the hydrogel nanoparticles is the incorporation 
of the bait [9,10], which captures HGH with high affinity. We screened 
a series of nine chemical baits for HGH affinity within a urine matrix. 
The affinity ranges from KD = 10-9 to 10-12 M. We selected the bait that 
had the highest affinity, which was Remazol Brilliant Blue R (RBB, 
Figure 1). This previously unpublished bait for HGH had an affinity ten 
times greater than Cibacron Blue F3GA [12,13] (Figure 2).
In solution
Growth Hormone
Capture
Growth Hormone
Release
Immunoassay
Figure 1: Capturing hydro gel nanoparticles pre-processing step. Well 
disperse and buoyant particles are introduced in the urine and all the solution 
phase Human Growth Hormone (HGH) is sequestered. Particles are separated 
from the urine and captured HGH is eluted and analyzed with a sandwich 
immunoassay.
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Concentration factor calculation
Enhanced detection sensitivity is achieved because the nanoparticles 
effectively harvest virtually 100% of the HGH from the full 30 mL urine 
volume, and concentrate the urinary HGH down to a volume of 300 µL. 
The increase in effective concentration of HGH is: 
(vs/ve)·C=Ci                     (1)
Where vs. = original sample volume, ve = volume of nanoparticle 
eluate, C = initial concentration of analyte in the sample, and Ci=final 
increased expected concentration. Consequently a 100 times higher 
concentration of HGH is introduced into the Immulite assay, compared 
to the unconcentrated urine. The nanoparticles are buoyant open mesh 
(>95% solute) hydrogel spheres (Figure 3A) containing a core with an 
immobilized high affinity chemical bait. When mixed with the urine, 
the nanoparticles remain in colloid suspension to achieve extremely 
rapid access [10,11] and sequestration of the HGH target analyte. The 
bait binds HGH with high affinity (KD<10-12 M, Figure 1), such that no 
detectable HGH can be measured outside the nanoparticles in the fluid 
phase.  
Concentration method verification
The nanoparticle concentration method was verified with standard 
samples that were run by trained personnel in a blind fashion, N = 21. 
The acceptance criteria were percentage difference (Diff %) < 10%, as 
defined by the following equation:
Diff% = (Meas - True)/True *100                      (2)
Where true is the true HGH concentration in the blind standard 
sample and Meas is the HGH concentration value obtained by 
nanoparticle Immulite assay performed in a blind fashion. 
100% of the samples passed the 10% criteria (Table 1).
Full process precision
The full-process within-run CV for the nanoparticle based 
measurement of urinary HGH was 9.0% (N=10), with virtually 100% 
HGH capture efficiency and 100% elution yield (Figure 3B, Initial 
Solution Average (CV) ng/mL =0.128 (4.0%CV) ng/mL; Supernatant 
<0.05 ng/mL; Eluate Actual Measurement, Average (CV) =2.095 
(9.0%CV) ng/mL; Calculated 100% yield 2.048 ng/mL). The between 
run precision (%CV) without the particles was 9.5% and the between 
run precision (%CV) with the nanoparticles was 8.1%. The HGH 
concentration in the supernatant following nanoparticle incubation 
was always below the limit of detection for the Immulite. The between 
run analysis was done over 2 working weeks. (Initial Solution Average 
(CV) ng/mL = 0.106 (9.5%CV) ng/mL; Supernatant <0.05 ng/mL; 
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Figure 2: Dissociation constant (KD) values calculated for nine organic 
chemical baits assuming hGH-bait equimolar binding. AB22 = Acid blue 22, 
RBB = Remazol brilliant blue R, AB1 = Acid black 1, CB = Cibacron blue F3GA, 
DO3 = Disperse orange 3, PRR = Pararosaniline base, R250 = Brilliant blue 
R250, R123 = Rhoda mine 123, AAc = acrylic acid. 
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Figure 3. A) Atomic force microscope images demonstrate uniformity of the 
spherical poly (NIPAm/RBB) nanoparticles. B) Nanoparticle-Immulite GH assay 
has a within run CV = 9% (over ten replicates) and virtually 100% yield. Mean 
+/- CV. IS = initial solution, S = Supernatant, E = nanoparticle eluate, C100% 
= calculated GH concentration based on 100% yield. C) And D) Linearity of 
the immunoassay (9 calibrator values, range 0.750-0.05 ng/mL) with and 
without nanoparticle preprocessing, respectively. Nanoparticle preprocessing 
maintains the linearity of the immunoassay (R2=0.986, 0.982, with and without 
the nanoparticles, respectively). 
True [Ng/Ml] Measured [Ng/Ml] Diff %
2.95 2.91 1.37
3.61 3.6 0.28
1.22 1.2 1.67
0.454 0.437 3.89
0.15 0.154 -2.60
0.38 0.385 -1.30
1.63 1.51 7.95
4.35 4.52 -3.76
6.89 6.76 1.92
0.348 0.34 2.35
0.354 0.389 -9.00
10.000 10.6 -5.66
0.360 0.336 7.14
2.200 2.14 2.80
0.083 0.085 -2.35
7.610 7.58 0.40
2.130 2.140 -0.47
1.470 1.390 5.76
2.440 2.430 0.41
0.891 0.879 1.37
0.778 0.757 2.77
Table 1:Nanoparticle pre-processing step passed the concentration method 
verification test in our laboratory, N=21. TRUE = true value of HGH concentration 
in the standard sample, MEASURED = HGH concentration measured in the 
standard sample in a blind fashion, DIFF% = (MEASURED - TRUE)/TRUE *100. 
Acceptability criteria = DIFF% < 10%.
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Eluate Actual Measurement, Average (CV) =0.576 (8.1%CV) ng/mL; 
Average total yield (CV) = 91% (13.2%CV).
Full process linearity
Linearity of the immunoassay (9 calibrator values, range 0.750-0.05 
ng/mL) was equivalent with and without nanoparticle pre-processing 
(Figure 3C and 3D, Slope (standard deviation) =0.74 (0.03), 0.79 (0.04); 
Intercept (standard deviation) =-0.02 (0.02),-0.02 (0.02); R2=0.986, 
0.982; Residual standard deviation=0.0286, 0.0347 with and without 
the nanoparticle processing, respectively). 
Reference values for HGH in spot urine
In our cohort of volunteers, the 95% reference values for hGH in 
spot urine normalized to specific gravity were 0.64 - 16.85 pg/mL (0.05 
-5.82 ng/g creatinine) (Table 2). Reference values and confidence intervals 
were calculated with the bootstrap method [14] in R Statistical Software 
[15]. These data reveal that there is a one thousand fold difference in the 
concentration of physiologic HGH in spot urine compared to the value in 
serum for the same patient, measured at the same point in time (Table 2). 
Inter-laboratory proficiency assessment
To verify that this methodology could be validated across multiple 
laboratories, we did a side by side comparison of nanoparticle 
preprocessed urine in two different international laboratories using 
two different immunoassays. The Immulite immunoassay as described 
above was conducted in George Mason University, USA and a recently 
developed research grade immunoassay validated for serum samples 
[16] was performed in IMIM Hospital del Mar, Spain. Four urine 
proficiency samples spiked with recombinant hGH were prepared 
and incubated with 1 mL of poly(NIPAm/RBB) nanoparticles. The 
nanoparticle-processed eluate was measured by the USA and Spain 
laboratories independently. The correlation, spanning the range of 
0.003 – 0.3 ng/mL calculated urine concentration (0.08 – 11 ng/mL 
measured hGH urine concentration), was y = 0.8454x + 0.2386, R2 = 
0.9967, where x = USA results and y = Spain results. 
Thus, nanoparticle preprocessing constitutes a reliable means of 
establishing a normal baseline value for HGH in urine. The important 
question can now be addressed as to whether the excretion of HGH 
in the urine has longer time course than the spike of HGH in serum 
following exogenous administration. Moreover, it will now be possible 
to study factors that affect urinary HGH excretion and isoform 
proportions. This is important because urinary HGH measurement 
may permit the detection of HGH doping that would otherwise be 
missed with serum testing [6]. 
Bait functionalized hydrogel nanoparticles [10,11] are a cost 
effective, user friendly technology that, in this study, permitted the 
reliable measurement of a low abundance protein analyte (HGH) 
in urine with a clinical grade immunoassay that until now is used 
for serum/plasma based analysis.  Once the correct bait chemistry is 
matched to optimal analyte capture, this nanoparticle technology can 
be applied to the measurement of any analyte in any body fluid using 
any appropriate measurement platform ranging from immunoassays to 
mass spectroscopy-based multiple reaction monitoring [10]. 
Urine hGH concentration, pg/mL Urine hGH concentration, ng/g creatinine Serum hGH concentration, ng/mL
2.5 percentile (0.90 confidence interval) 0.64 (0.52- 0.84) 0.05 (0.04 – 0.06) 0.13 (0.11- 0.19)
97.5 percentile (0.90 confidence interval) 16.85 (9.92- 28.369) 5.82 (2.34 – 9.7) 16.03 (7.75- 23.2)
Median 2.75 0.39 0.41
Average 5.01 0.98 2.42
Table 2: Reference Values of spot urine HGH measured with nanoparticle-Immulite assay and serum HGH measured with Immulite Growth Hormone test.
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